Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2000-02-29
2001-06-12
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
Reexamination Certificate
active
06245818
ABSTRACT:
The present invention relates to a medicament for the prophylactic and/or therapeutic improvement of the duration of mammalian muscle function and/or treatment of mammalian muscle disorders or diseases, comprising at least one type of xanthophylles, especially astaxanthin. The invention also relates to the use of at least one type of xanthophylles for the production of such a medicament and to a method of prophylactic and/or therapeutic improvement of the duration of mammalian muscle function and/or treatment of mammalian muscle disorders or diseases, e.g. equine Exertional Rhabdomyolysis.
BACKGROUND OF THE INVENTION
Exertional rhabdomyolysis, also referred to as exertional myopathy, tying-up syndrome, azoturia, or Monday morning disease, is probably the most common muscle disorder in horses. Predisposing or associated factors that have been implicated in the pathogenesis of this condition include electrolyte imbalances, hypothyroidism, and vitamin E-selenium deficiency. Therefore, treatment of horses affected by exertional rhabdomyolysis have included pain relief, rehydration and correction of electrolyte abnormalities (See e.g. The Horse: Diseases and Clinical Management, edited by C. N. Kolbluk, T. R. Ames, R. J. Geor, W. B. Saunders Company, Philadelphia, 1995, pp. 809-810).
Xanthophylles, including astaxanthin, is a large group of carotenoids containing oxygen in the molecule in addition to carbon and hydrogen. The carotenoids are produced de novo by plants, fungi and some bacteria. Astaxanthin, in the form of naturally produced algal meal of cultured Haematococcus sp., has been marketed as antioxidant for mammals, especially humans.
DESCRIPTION OF THE INVENTION
The present invention provides a medicament for the prophylactic and/or therapeutic improvement of the duration of mammalian muscle function and/or treatment of mammalian muscle disorders or diseases, comprising at least one type of xanthophylles.
In a preferred embodiment the type of xanthophyll is astaxanthin, particularly in a form esterified with fatty acids.
In a most preferred embodiment the astaxanthin in esterified form with fatty acids is algal meal of cultured Haematococcus sp.
Examples of mammalian muscle disorders or diseases include human myopaties and connective tissue diseases, as well as equine myopaties and connective tissue diseases.
In a particular embodiment of the invention, the mammalian muscle disorder is equine Exertional Rhabdomyolysis.
The medicament according to the invention may comprise a mixture of different types of xanthophylles or different forms of the same xanthophyll, such as a mixture of synthetic astaxanthin and naturally produced astaxanthin.
The medicament of the invention may comprise additional ingredients which are pharmacologically acceptable inactive or active in prophylactic and/or therapeutic use, such as flavoring agents, excipients, diluents, carriers, etc., and it may be presented in a separate unit dose or in admixture with food or feed. Examples of separate unit doses are tablets, gelatin capsules and predetermined amounts of solutions, e. g. oil solutions, or emulsions, e.g. water-in-oil or oil-in-water emulsions. Examples of food in which the preparation of the invention may be incorporated is dairy products, such as joughurt, chocolate and cereals. The daily doses of the xanthophyll in the medicament of the invention will normally be in the range of 0.01 to 1 mg per kg body weight.
The present invention also comprises the use of at least one type of xanthophylies in the preparation of a medicament for the prophylactic and/or therapeutic improvement of the duration of mammalian muscle function and/or treatment of mammalian muscle disorders or diseases. Once again, the preferred type of xanthophyll is astaxanthin, particularly in a form esterified with fatty acids, e.g. in the form of algal meal of cultured Haematococcus sp.; and in a specific embodiment the mammalian muscle disorder is equine Exertional Rhabdomyolysis.
Further, the invention comprises a method of prophylactic and/or therapeutic improvement of the duration of mammalian muscle function and/or treatment of mammalian muscle disorders or diseases, e.g. equine Exertional Rhabdomyolysis, comprising administration to said mammal of a prophylactically and/or therapeutically effective dose of a medicament according to the invention.
REFERENCES:
patent: WO 8503226 (1985-08-01), None
patent: WO 9500130 (1995-01-01), None
patent: WO 9623489 (1996-08-01), None
patent: 0770385 (1997-05-01), None
Patent Abstracts of Japan, vol. 14, No. 215, C-716, abstract of JP 2-49091 A, Feb. 19, 1990.
Patent Abstracts of Japan, vol. 18, No. 307, C-1211, abstract of JP 6-65033 A, Mar. 8, 1994.
Astacarotene AB
Bacon & Thomas
Criares Theodore J.
Kim Jennifer
LandOfFree
Medicament for improvement of duration of muscle function or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicament for improvement of duration of muscle function or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for improvement of duration of muscle function or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2544623